Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -81.60% is 85% above its 4-year average of -547.21%, near the high end of its 4-year range (-1865.68%–22.34%).
94.07% above its 12-month average of -1375.39%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.37%.
RETURN ON ASSETS (ROA)
-81.60%
RETURN ON ASSETS (ROA) AVG TTM
-1375.39%
RETURN ON ASSETS (ROA) AVG 3Y
-681.84%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+94.07%
CURRENT VS 3Y AVG
+88.03%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.18%
median of 674 covered companies
CURRENT VS SECTOR MEDIAN
-170.33%
vs the sector median at left
Aspire Biopharma Holdings, Inc.
Market Cap
$1.02M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
N/A
Market Cap
$1.06M
Return on Assets (ROA)
-44.32%
TTM Avg
-57.72%
3Y Avg
-286.30%
5Y Avg
-215.47%
Market Cap
$1.10M
Return on Assets (ROA)
-8.84%
TTM Avg
-4.56%
3Y Avg
8.88%
5Y Avg
8.88%
Market Cap
$1.14M
Return on Assets (ROA)
-147.60%
TTM Avg
-223.87%
3Y Avg
-1843.76%
5Y Avg
-4349.14%
Market Cap
$1.20M
Return on Assets (ROA)
-64.99%
TTM Avg
-31.34%
3Y Avg
-98.36%
5Y Avg
-79.15%
Market Cap
$866624.00
Return on Assets (ROA)
-1066.69%
TTM Avg
-314.14%
3Y Avg
-238.72%
5Y Avg
-174.21%
Market Cap
$873508.00
Return on Assets (ROA)
-65.16%
TTM Avg
-80.06%
3Y Avg
-104.26%
5Y Avg
-73.53%
Market Cap
$856468.00
Return on Assets (ROA)
-160.53%
TTM Avg
-148.83%
3Y Avg
-175.96%
5Y Avg
-127.43%
Market Cap
$1.16M
Return on Assets (ROA)
-247.39%
TTM Avg
-97.35%
3Y Avg
-1378.80%
5Y Avg
-1078.71%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | $1.02M | -81.60% | -1375.39% | -681.84% | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | -44.32% | -57.72% | -286.30% | -215.47% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | -8.84% | -4.56% | 8.88% | 8.88% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.14M | -147.60% | -223.87% | -1843.76% | -4349.14% |
| IM Cannabis Corp. (IMCC)vs › | $1.20M | -64.99% | -31.34% | -98.36% | -79.15% |
| GlucoTrack, Inc. (GCTK)vs › | $866624.00 | -1066.69% | -314.14% | -238.72% | -174.21% |
| Bone Biologics Corporation (BBLG)vs › | $873508.00 | -65.16% | -80.06% | -104.26% | -73.53% |
| Decoy Therapeutics Inc. (DCOY)vs › | $856468.00 | -160.53% | -148.83% | -175.96% | -127.43% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.16M | -247.39% | -97.35% | -1378.80% | -1078.71% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $827564.00 | -63.04% | -106.06% | -121.33% | -96.21% |
ROA
-81.6%
ROE
-94.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -1865.68% |
| 2024-12-31 | -885.11% |
| 2023-12-31 | 22.34% |
| 2022-12-31 | 1.11% |
| 2021-12-31 | -8.69% |
